CL2019002840A1 - Formas cristalinas de (s)-afoxolaner. - Google Patents

Formas cristalinas de (s)-afoxolaner.

Info

Publication number
CL2019002840A1
CL2019002840A1 CL2019002840A CL2019002840A CL2019002840A1 CL 2019002840 A1 CL2019002840 A1 CL 2019002840A1 CL 2019002840 A CL2019002840 A CL 2019002840A CL 2019002840 A CL2019002840 A CL 2019002840A CL 2019002840 A1 CL2019002840 A1 CL 2019002840A1
Authority
CL
Chile
Prior art keywords
afoxolaner
crystalline forms
crystal forms
forms
elaboration
Prior art date
Application number
CL2019002840A
Other languages
English (en)
Inventor
De Vries Roelof Johannes Gorter
Bruno Baillon
Sylvaine Lafont
De Saint Michel Myriam Gay
Stephane Kozlovic
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of CL2019002840A1 publication Critical patent/CL2019002840A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Secondary Cells (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

FORMAS CRISTALINAS DEL COMPUESTO DE FÓRMULA (IA) Y PROCESOS DE ELABORACIÓN DE LAS FORMAS CRISTALINAS. TAMBIÉN SE PROVEEN COMPOSICIONES QUE COMPRENDEN LAS FORMAS CRISTALINAS Y MÉTODOS DE USO DE DICHAS FORMAS CRISTALINAS.
CL2019002840A 2017-04-05 2019-10-04 Formas cristalinas de (s)-afoxolaner. CL2019002840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
CL2019002840A1 true CL2019002840A1 (es) 2020-01-10

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002840A CL2019002840A1 (es) 2017-04-05 2019-10-04 Formas cristalinas de (s)-afoxolaner.

Country Status (23)

Country Link
US (2) US10662163B2 (es)
EP (1) EP3606911A1 (es)
JP (1) JP7222909B2 (es)
KR (1) KR102612648B1 (es)
CN (1) CN111032634A (es)
AR (1) AR111412A1 (es)
AU (1) AU2018250304B2 (es)
BR (1) BR112019021072A2 (es)
CA (1) CA3059114A1 (es)
CL (1) CL2019002840A1 (es)
CO (1) CO2019011980A2 (es)
EA (1) EA201992360A1 (es)
IL (1) IL269792B (es)
MD (1) MD20190080A2 (es)
MX (1) MX2019011931A (es)
MY (1) MY188420A (es)
PH (1) PH12019502277A1 (es)
SG (1) SG11201909229SA (es)
TW (1) TWI782976B (es)
UA (1) UA125727C2 (es)
UY (1) UY37665A (es)
WO (1) WO2018187623A1 (es)
ZA (1) ZA201906464B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner
CN115768753B (zh) * 2020-06-19 2024-04-26 东莞市东阳光动物保健药品有限公司 一种gaba抑制剂的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI461411B (zh) * 2007-08-17 2014-11-21 Du Pont 製備５－鹵烷基－４，５－二氫異唑衍生物之方法
KR102060464B1 (ko) * 2010-05-27 2019-12-30 이 아이 듀폰 디 네모아 앤드 캄파니 4-[5-[3-클로로-5-(트라이플루오로메틸)페닐]-4,5-다이하이드로-5-(트라이플루오로메틸)-3-아이속사졸릴]-n-[2-옥소-2-[(2,2,2-트라이플루오로에틸)아미노]에틸]-1-나프탈렌카르복스아미드의 결정 형태
TWI567064B (zh) * 2011-09-12 2017-01-21 龍馬躍有限公司 包含異唑啉活性劑之殺寄生蟲組合物、方法及其用途
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG10201912724SA (en) * 2015-04-08 2020-02-27 Boehringer Ingelheim Animal Health Usa Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
BR112018070663A2 (pt) 2016-04-06 2019-02-05 Merial Inc processo para a preparação de compostos de isoxazolina enantiomericamente enriquecidos - solvato de tolueno cristalino de (s)-afoxolaner
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner

Also Published As

Publication number Publication date
US20180354917A1 (en) 2018-12-13
IL269792B (en) 2022-04-01
ZA201906464B (en) 2021-08-25
BR112019021072A2 (pt) 2020-05-12
UA125727C2 (uk) 2022-05-25
CA3059114A1 (en) 2018-10-11
KR102612648B1 (ko) 2023-12-11
JP2020513010A (ja) 2020-04-30
EA201992360A1 (ru) 2020-09-02
CN111032634A (zh) 2020-04-17
IL269792A (en) 2019-11-28
SG11201909229SA (en) 2019-11-28
AU2018250304B2 (en) 2022-03-03
KR20190136055A (ko) 2019-12-09
AU2018250304A1 (en) 2019-10-31
MX2019011931A (es) 2020-01-13
PH12019502277A1 (en) 2020-09-14
CO2019011980A2 (es) 2020-02-18
UY37665A (es) 2018-10-31
MY188420A (en) 2021-12-08
AR111412A1 (es) 2019-07-10
TWI782976B (zh) 2022-11-11
US10662163B2 (en) 2020-05-26
US20200270219A1 (en) 2020-08-27
TW201841895A (zh) 2018-12-01
JP7222909B2 (ja) 2023-02-15
US11130739B2 (en) 2021-09-28
WO2018187623A1 (en) 2018-10-11
MD20190080A2 (ro) 2020-04-30
EP3606911A1 (en) 2020-02-12
WO2018187623A8 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
AR109393A1 (es) Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CL2017003486A1 (es) Lactamas bicíclicas y métodos de uso de las mismas
SV2017005467A (es) Formas sólidas de un inhibidor ask1.
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
CL2017000505A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CL2020003083A1 (es) Inhibidores de masp-2 y métodos de uso
CL2017000540A1 (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.